Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 0

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 0
---
(Unaudited)

   (Expressed in thousands except share and per share data)

   1. Nature of operations

   General
   
  Grace Therapeutics, Inc. (formerly
known as Acasti Pharma Inc.) (“Acasti Delaware” or “the Company”), is a
Delaware corporation that, as further described below, previously existed under
the laws of the Province of Québec, Canada (“Acasti Québec”), before changing
its jurisdiction on October 1, 2024 to the Province of British Columbia, Canada
(“Acasti British Columbia”). On October 7, 2024, Acasti British Columbia
changed its jurisdiction to the State of Delaware in the United States of
America. Effective October 28, 2024, the Company changed its corporate name to
Grace Therapeutics, Inc.  
   Continuance and Domestication

   On October 1, 2024, Acasti Québec changed its jurisdiction of incorporation from the Province of Québec in Canada to the Province of British Columbia in Canada pursuant to a “continuance” effected in accordance with Chapter XII of the Business Corporations Act (Québec) (the “Continuance”). Subsequently on October 7, 2024 (the “Effective Date”), Acasti British Columbia changed its jurisdiction of incorporation from the Province of British Columbia in Canada to the State of Delaware in the United States of America pursuant to a “continuance” effected in accordance with Section 308 of the Business Corporations Act (British Columbia) and a “domestication” (the “Domestication”) under Section 388 of the General Corporation Law of the State of Delaware. Both the Continuance and the Domestication were approved by the Company’s shareholders at the Company’s Annual and Special Meeting of Shareholders held on September 30, 2024.
   
   Prior to the Continuance and Domestication, the Company’s Class A common shares, without par value per share (“Common Shares”), were listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ACST.” Upon the effectiveness of the Continuance, each outstanding Class A common share of Acasti Québec at the time of the Continuance remained issued and outstanding as a common share, without par value per share, of Acasti British Columbia. Upon effectiveness of the Domestication, each outstanding common share of Acasti British Columbia at the time of the Domestication automatically